A new review published in the *Journal of the Endocrine Society* finds evidence that polyendocrine metabolic ovarian syndrome (PMOS)—formerly known as polycystic ovary syndrome (PCOS)—may be associated with brain changes and Alzheimer’s disease–related biomarkers, raising questions about potential dementia risk. The review emphasizes that the findings are associations and do not prove that PMOS itself causes Alzheimer’s disease.

Across the sources, the central explanation is that metabolic conditions commonly seen alongside PMOS may be the more relevant pathway. These include insulin resistance, obesity, type 2 diabetes, and elevated cholesterol, which are already established risk factors for cognitive decline. Some studies reviewed also report differences in aspects of cognition and brain structure or function, alongside hormonal changes and potential overlap with mechanisms seen in Alzheimer’s, such as involvement of proteins like amyloid and tau.

Experts quoted in the coverage stress caution: the strength of brain and biomarker differences may vary, and they appear less pronounced in metabolically healthy groups. The review and commentators also note that lifestyle and medical management of metabolic risk factors—such as exercise, a Mediterranean-style diet, sleep, and controlling blood sugar and cholesterol—may support long-term brain health, though more research is needed.